Semaglutide is a medication approved by the FDA for the treatment of diabetes and over-weight or obesity. In studies for these conditions, semaglutide and other medications like it have shown improved memory function, less build-up of brain plaque, and a reduction of inflammation in the body. All of these effects may be beneficial in patients with mild memory loss. This study is undertaken to demonstrate whether semaglutide can help patients with mild Alzheimer’s disease.

Criteria to participate

Some of the criteria patients must satisfy to participate are:

  • Male or female between 55 and 85 years old
  • Have a study partner (i.e. someone who is with you for 8 hours or more each week and would be willing to come to the study center about twice a year with you)
  • Demonstrates mild memory loss with testing
  • Has a positive PET (brain scan) for amyloid plaque
  • Is able to have an MRI scan (e.g. no metal in your head or upper torso)
  • Has no medical conditions which may also cause memory loss (e.g. Parkinson’s, uncontrolled sleep apnea, and history or stroke)

 About the Study

Once the study criteria are met, the patient will receive either the study medication or a placebo for the duration of the study; neither the patient nor the doctor will know which is assigned. At the beginning of the study, MRI scans and an amyloid PET scan will be conducted. The study medication is taken once daily by mouth. The study will last for 2 to 3 years. There is no cost to the patient for medical care provided in the study nor for any of the scans, memory testing, or medication.

Current Studies



Study medications

NCT number

Study Status

EVOKE Novo Nordisk semaglutide NCT04777409  Closed